{"symbol":"SYK","fiscalQuarter":"Q2-2026","reportDate":"2026-07-30","reportTime":"AMC","status":"upcoming","company":{"name":"Stryker Corporation","sector":"Health Care","industry":"Health Care Equipment"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/SYK/earnings/Q2-2026","estimates":{"consensusEps":3.6791,"consensusRevenue":6719.22,"epsLow":3,"epsHigh":3.81,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Stryker Corporation (SYK) is a leading medical technology company that develops innovative products and services in the healthcare sector, particularly in surgical equipment and orthopedic implants. With a market cap of $125 billion, Stryker plays a crucial role in improving patient outcomes and enhancing surgical procedures, making it a key player in the growing health care equipment industry.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a critical measure of a company's profitability and will indicate how well Stryker is managing costs and generating income.","consensus":"$3.68"},{"name":"Revenue","why":"Revenue growth reflects the company's ability to sell its products and services effectively, which is essential for sustaining its market position.","consensus":"$6.7B"}],"lastQuarterRecap":{"summary":"In Q1-2026, Stryker reported an EPS of $2.60, which was below the expected $2.98, resulting in a negative surprise of 12.63%. The stock did not move significantly the following day, indicating market uncertainty.","promises":["Focus on innovation in product development.","Commitment to expanding market share in surgical equipment.","Plans to improve operational efficiency."]},"wallStreetExpectations":{"summary":"Analysts are cautiously optimistic about Stryker's upcoming earnings, expecting a rebound in EPS and revenue after a disappointing last quarter. The consensus estimates suggest a recovery in performance.","bullCase":"If Stryker beats EPS expectations and shows strong revenue growth, it could signal a successful turnaround and renewed investor confidence.","bearCase":"Conversely, if the company misses estimates again, it may raise concerns about its growth trajectory and operational challenges, leading to further stock declines."},"optionsSignal":{"impliedMove":"1.09%","context":"The options market is pricing in a modest move, suggesting that investors are uncertain about the upcoming earnings results."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"-12.63%","reaction":"+0.00%"},{"quarter":"Q4-2025","epsSurprise":"+1.71%","reaction":"-0.99%"},{"quarter":"Q3-2025","epsSurprise":"+1.66%","reaction":"-0.17%"},{"quarter":"Q2-2025","epsSurprise":"+2.05%","reaction":"-1.92%"},{"quarter":"Q1-2025","epsSurprise":"+4.18%","reaction":"+0.02%"}],"pivotalQuestions":[{"question":"Will Stryker achieve an EPS of at least $3.68?","whyItMatters":"This EPS figure is critical for restoring investor confidence after the previous quarter's miss."},{"question":"How does Stryker plan to address operational challenges that led to the last quarter's underperformance?","whyItMatters":"Management's commentary on operational improvements will be key to understanding future growth potential."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $3.70 or higher, along with revenue exceeding $6.8B, would confirm a strong recovery.","bearTrigger":"An EPS below $3.00 would signal ongoing operational issues and raise concerns about future growth.","context":"This quarter's performance is crucial for Stryker as it seeks to regain momentum after a disappointing previous quarter."},"scenarioPlaybook":{"beatAndRaise":"If Stryker beats expectations, history suggests the stock could see a modest increase, confirming a positive turnaround narrative.","inLineCautious":"If results are in line with expectations, the stock may react neutrally, reflecting ongoing investor caution.","miss":"A miss could lead to a decline in stock price, with historical patterns suggesting a potential drop of around 0.00%."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter miss + options pricing rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating Stryker's potential for a significant rebound in EPS and revenue, given the company's historical ability to innovate and capture market share.","supportingPoints":["Stryker has consistently beaten EPS estimates in the past, with an 88% beat rate.","The options market is pricing a relatively low move, suggesting that expectations may be muted.","Management's focus on operational efficiency could lead to better-than-expected results."],"riskToConsensus":"If Stryker's EPS comes in below $3.00, it could undermine the entire recovery narrative."},"whatToListenFor":["Details on new product launches and their expected impact on revenue.","Any updates on cost-cutting measures and operational improvements.","Insights into market share trends in key product segments.","Management's outlook on the competitive landscape and pricing pressures.","Clarification on the company's strategy for addressing recent operational challenges."],"metaDescription":"Stryker (SYK) reports Q2 2026 earnings July 30. Analysts expect $3.68 EPS on $6.7B revenue. Here's what to watch."}}